Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Montelukast 5 mg Chewable Tablets in Healthy Volunteers
NCT03898193Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of montelukast in asthma and allergic rhinitis (AR) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration (Cmax) and Area Under the Curve to Last Timepoint (AUC0-t). Started Mar 2019; status: completed.
02
Drugs
montelukast
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03898193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03898193.